A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/17330838

Cancer 2007 Apr 1 109 7 1323-30

Download in:

View as

Triples

General Info

PMID
17330838